T3D-959
Mild to Moderate Alzheimer's Disease
Phase 2Active
Key Facts
About T3D Therapeutics
T3D Therapeutics is pioneering a novel approach to treating Alzheimer's disease by targeting brain 'starvation'—a core metabolic dysfunction characterized by impaired glucose and lipid metabolism. Its lead candidate, T3D-959, is a first-in-class, orally administered dual nuclear receptor agonist that has completed a Phase 2 trial (PIONEER) in mild-to-moderate Alzheimer's patients. The company is positioning itself as a potential disruptor in the neurodegenerative disease space, with a secondary focus on Huntington's Disease, and is actively advancing its clinical program based on recent biomarker and cognitive data presentations.
View full company profile